TY  - JOUR
T1  - Interval cancers in a FOBT-based colorectal cancer population screening programme
T2  - implications for stage, gender and tumour site
A1  - Steele,R. J. C.
A1  - McClements,P.
A1  - Watling,C.
A1  - Libby,G.
A1  - Weller,D.
A1  - Brewster,D .H.
A1  - Black,R.
A1  - Carey,F. A.
A1  - Fraser,C. G.
AU  - Steele,R. J. C.
AU  - McClements,P.
AU  - Watling,C.
AU  - Libby,G.
AU  - Weller,D.
AU  - Brewster,D .H.
AU  - Black,R.
AU  - Carey,F. A.
AU  - Fraser,C. G.
PY  - 2012/4/1
Y1  - 2012/4/1
N2  - Background: Between 2000 and 2007, a demonstration pilot of biennial guaiac faecal occult blood test (GFOBT) screening was carried out in Scotland. Methods: Interval cancers were defined as cancers diagnosed within 2 years (ie, a complete screening round) of a negative GFOBT. The stage and outcome of the interval cancers were compared with those arising contemporaneously in the non-screened Scottish population. In addition, the gender and site distributions of the interval cancers were compared with those in the screen-detected group and the non-screened population. Results: Of the cancers diagnosed in the screened population, interval cancers comprised 31.2% in the first round, 47.7% in the second, and 58.9% in the third, although this was due to a decline in the numbers of screen-detected cancers rather than an increase in interval cancers. There were no consistent differences in the stage distribution of interval cancers and cancers from the non-screened population, and, in all three rounds, both overall and cancer-specific survival were significantly better for patients diagnosed with interval cancers (p
AB  - Background: Between 2000 and 2007, a demonstration pilot of biennial guaiac faecal occult blood test (GFOBT) screening was carried out in Scotland. Methods: Interval cancers were defined as cancers diagnosed within 2 years (ie, a complete screening round) of a negative GFOBT. The stage and outcome of the interval cancers were compared with those arising contemporaneously in the non-screened Scottish population. In addition, the gender and site distributions of the interval cancers were compared with those in the screen-detected group and the non-screened population. Results: Of the cancers diagnosed in the screened population, interval cancers comprised 31.2% in the first round, 47.7% in the second, and 58.9% in the third, although this was due to a decline in the numbers of screen-detected cancers rather than an increase in interval cancers. There were no consistent differences in the stage distribution of interval cancers and cancers from the non-screened population, and, in all three rounds, both overall and cancer-specific survival were significantly better for patients diagnosed with interval cancers (p
KW  - Adult
KW  - Aged
KW  - Article
KW  - Cancer localization
KW  - Cancer prognosis
KW  - Cancer screening
KW  - Cancer specific survival
KW  - Cancer staging
KW  - Clinical evaluation
KW  - Colorectal cancer
KW  - Controlled study
KW  - Diagnostic accuracy
KW  - Disease duration
KW  - Female
KW  - Human
KW  - Major clinical study
KW  - Male
KW  - Occult blood test
KW  - Overall survival
KW  - Pathological anatomy
KW  - Priority journal
KW  - Sex difference
UR  - http://www.scopus.com/inward/record.url?partnerID=yv4JPVwI&eid=2-s2.0-84857798015&md5=51126474df03e827f6ebb04dd4945468
U2  - 10.1136/gutjnl-2011-300535
DO  - 10.1136/gutjnl-2011-300535
M1  - Article
JO  - Gut
JF  - Gut
SN  - 0017-5749
IS  - 4
VL  - 61
SP  - 576
EP  - 581
ER  -